7-Hydroxymitragynine (7-OH)

7-Hydroxymitragynine (7-OH) occurs only in trace amounts in the natural kratom leaf, where it is a minor alkaloid; most of the 7-OH that affects the body is produced when the liver metabolizes mitragynine, kratom's primary alkaloid. The critical distinction — and the core of this page's harm-reduction value — is between whole-leaf kratom and the concentrated, isolated, or semi-synthetic 7-OH products that spread rapidly across U.S. smoke shops and gas stations in 2024-2025. Sold as tablets, gummies, drink mixes, and liquid 'shots' and marketed separately from traditional kratom, these products deliver far more 7-OH than the leaf ever naturally contains. The FDA characterizes them as 'concentrated 7-OH opioid products' and warns they are effectively unregulated opioids being sold over the counter.

7-Hydroxymitragynine is a potent agonist at the mu-opioid receptor (MOR), the same receptor engaged by morphine and other classical opioids, acting predominantly at the mu-opioid subtype. Published pharmacology characterizes it as substantially more potent and efficacious at the MOR than mitragynine itself, and as a G-protein-biased agonist — a signaling profile that differs from classical opioids. In animal antinociception studies, subcutaneous 7-OH was reported to be roughly four-to-six times more potent than morphine (about 5.7 times in the mouse tail-flick test and 4.4 times in the hot-plate test). Its opioid activity at the MOR is what accounts for both its analgesic effects and its opioid-type risk profile.

Because 7-OH acts as a mu-opioid receptor agonist, its effects resemble those of other opioids — analgesia, sedation, and euphoria — rather than the milder, more stimulant-like profile many users associate with low-dose whole-leaf kratom. The central concern with the concentrated 7-OH products that emerged in 2024-2025 is that they present a far stronger and less predictable opioid effect than the natural leaf, while often being sold in candy-like or beverage formats. Effects and their intensity vary with the product and the individual; because these products are unregulated, their actual 7-OH content is frequently unknown.

As an opioid agonist, 7-hydroxymitragynine carries the characteristic risks of the opioid class. Repeated use can produce tolerance, physical dependence, and an opioid-type withdrawal syndrome on discontinuation, and case reports and FDA reporting describe dependence developing with the concentrated products. The defining acute danger of any mu-opioid agonist is respiratory depression, the mechanism by which opioids cause fatal overdose. That hazard is amplified for isolated 7-OH products because their potency relative to morphine is high and their actual content is often unlabeled or unverified, so the amount consumed is difficult to gauge. Regulators have flagged the risk that these products are perceived as benign 'kratom' or wellness items while functioning as unregulated opioids. This section describes risks only; it is not use, dosing, or harm-reduction combination guidance.